Whereas IACS-16898 monotherapy did not yield any antitumor responses and anti-PD-1 plus anti-CTLA-4 (ICT) alone induced hyperprogression, the combination of IACS-16898 with ICT significantly decreased RMC tumor growth (Fig. 8e, f). Here, CTLA4 is linked to neoplasm.